GlobeNewswire

BrainChip Introduces a Powerful Neural Network Converter

Share

Create Low-Power, High Performance Event-Based Networks from Existing Convolutional Neural Networks

  • Landmark innovation in Neural Network design enables the next generation of AI Edge devices
  • Convert existing Convolutional Neural Networks to high performance, low power event-based Spiking Neural Networks
  • Utilize Industry Standard Neural Network Development Flows in a unified environment  and reduce computational overhead

SAN FRANCISCO, June 11, 2019 (GLOBE NEWSWIRE) -- BrainChip Holdings Ltd (ASX: BRN), the leading AI Edge company, today announced the availability of the Company’s powerful neural network converter which enables users to easily convert existing convolutional neural networks (CNNs) to an Akida compatible event-based spiking neural network (SNN). The converter is integrated with the Akida Development Environment (ADE) to provide network conversion and simulation.

This unified flow represents the world’s first commercially available development environment enabling both CNN and SNN implementations on the same hardware device while maintaining the inherent performance and power benefits of event-based neural networks.  Users can achieve higher performance with a native SNN and faster time-to-market by using the CNN to SNN converter and the ADE.

The new CNN to SNN conversion flow is designed for ease of use and utilizes standard text files. Users can implement many CNN architectures targeted at edge applications such as image processing, anomaly detection, ADAS, robotics, and key word spotting. The conversion maintains near full accuracy with increased performance while eliminating neural network computational overhead.  Post-conversion, the entire network is executed within the neural fabric of the Akida chip, which means that the host computational requirements of the neural network are eliminated. The host delivers the data to the chip and retrieves the results.

The conversion flow takes an input as a standard CNN description which the user modifies through a logical process to Akida compatible layers.  The modified network description is then processed through standard quantization and training. 

To optimize performance, the ADE supports programmable multiple bit-widths including binary, ternary and 4-bit for both weights and activations in each network layer.  Once the final network configuration is achieved, the resulting Akida compatible network description is output in industry standard .yml  and .dat files.  These files are run in the Akida emulation environment to generate performance information from the Akida device. 

The Akida development environment including the CNN to SNN conversion capability is available today in beta release and is scheduled for general release in the third quarter of 2019.  Upon request, the Company will provide detailed information about the performance of the Akida platform on industry standard benchmarks as well as novel implementations for Edge devices.

Roger Levinson, BrainChip COO commented, “The low power inherent in the Akida device will set a new standard in neural network design, implementation and performance.  With no barriers to utilizing the Akida platform, Edge solution developers will have their cake and eat it too.  They can leverage existing CNN solutions as well as incorporate next generation SNN solutions all in a single development environment and on a single device and achieve a low power solution without sacrificing performance.”

About BrainChip Holdings Ltd (ASX: BRN)

BrainChip Holdings Ltd is a leading provider of neuromorphic computing solutions, a type of artificial intelligence that is inspired by the biology of the human neuron. The Company’s revolutionary and proprietary new event driven neural network technology can learn autonomously, evolve and associate information just like the human brain. The proprietary technology is fast, completely digital and consumes very low power. The Company provides hardware focused solutions that address high-performance requirements in civil surveillance, gaming, financial technology, cybersecurity, ADAS, autonomous vehicles, and other advanced vision systems.  www.brainchip.ai

Company Contact:
Roger Levinson, COO
rlevinson@brainchip.ai

 

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor20.8.2019 17:45:00 CESTPress release

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor New patent granted in the United States by the USPTO protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035 This patent strengthens the protection of lanifibranor in the United States Daix (France), August 20, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the United States Patent and Trademark Office (USPTO) granted a new patent on August 20, 2019 that protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035. This new patent further strenghens Inventiva’s patent portfolio for lanifibranor, the Company’s lead product candidate, in the United States, which already comprised a New Chemical Entity (NCE) patent and a patent protect

PCI Biotech: Invitation to second quarter and first half 2019 results presentation20.8.2019 15:38:00 CESTPress release

Oslo, Norway, 20 August 2019 - PCI Biotech invites to a presentation of the company's second quarter and first half 2019 results on Wednesday 28 August 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday 28 August, 08:30am – 09:30am CEST (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo. The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to post@pcibiotech.com. The presentation will also be a live webcast and can be accessed through www.pcibiotech.com. It will be possible to post questions through the webcast console. The interim report and the presentation will be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 07:00am (CEST) on 28 August 2019. For further information, please contact: Ronny Skuggedal, CFO Email: rs@pcibiotech.no Mobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutica

Regarding resignation of member of the Supervisory Board20.8.2019 15:30:00 CESTPress release

We hereby inform that, T. Lukoševičius, a member of Supervisory Board of AB Klaipedos nafta (hereinafter – the Company) 20 August 2019 submitted a notice of resignation of members of Supervisory Board of the Company as of 3 September 2019 (this day is the last day of the mandate). It should be noted that, currently the Supervisory Board of the Company consists of 3 members, 2 of them are independent. After the resignation of T. Lukoševičius, the Ministry of Energy of the Republic of Lithuania will conduct the selection of new member of the Supervisory Board. The Supervisory Board is elected by the General Meeting of Shareholders for 4 years. If individual members of the Supervisory Board are elected, they shall be elected only until the end of the term of office of the current Supervisory Board. Jonas Lenkšas, Chief Financial Officer,+370 694 80594

SERSTECH AB: Boardmember Anna Werntoft resigns from the Board of Serstech20.8.2019 13:40:00 CESTPress release

Anna Werntoft will leave the board of directors effective on the 30th of September. The reason for her resignation is that she enters a new operational position with terms that does not allow external assignments. Serstech wishes Anna all the best in her new position and would like to thank her for her contribution while being on the Serstech Board. The Serstech will consist of three Board members until the vacant position is filled. The search for a replacement has started and will be concluded before the next annual general meeting. For further information, please contact: Stefan Sandor, CEO, Serstech AB tel: +46 739 606067 email: ss@serstech.com Thomas Pileby, Chairman of the Board, Serstech AB tel: +46 702 072643 email: tp@serstech.com Company website: www.serstech.com The information was submitted for publication, through the agency of the contact person set out above at 13:40 CET on August 20, 2019. Certified advisor to Serstech is Västra Hamnen Corporate Finance AB, phone: 040-2